Navigating treatment options for stage I and II NSCLC
Steven Kao, Christopher Cao and Caian Zhou tackle unanswered questions surrounding the treatment of early-stage NSCLC, including whether neoadjuvant or adjuvant immunotherapy could be the future of treatment.
Introduction

Which resection to perform for lung cancer – past, present, and future

Radiotherapy: State of the art in an era of evolving systemic therapies

Systemic therapies: How we got here

Systemic therapies: Immune checkpoint inhibitors

Panel discussion and Audience Q&A
